Authors
Xingyue Li, Jianxiang Wang, Yifei Wang, Fangfang Hu, Xin Yang, Jingjing Zhang, Haiyan Dong, Wen Lu
Published in
Nanomedicine (London, England). Pages 1-16. Sep 02, 2026. Epub Sep 02, 2026.
Abstract
To develop and characterize a targeted nano drug delivery system (nano-DDS), specifically fluorescently labeled Angiopep-2-conjugated PAMAM nanoparticles (FITC-APP NPs), and to evaluate its targeting efficiency and therapeutic potential both in vitro and in vivo.
Angiopep-2 was chemically conjugated to PAMAM via MAL-PEG-NHS crosslinking chemistry, followed by covalent attachment of fluorescein isothiocyanate (FITC) to yield FITC-APP NPs. Using brain microvascular endothelial cells (BMEC), glioma cells (C6 cells), and HEK-293 cells as a negative control, cell adhesion, uptake, and transport behavior were assessed. The cytotoxicity and antitumor efficacy against C6 cells were evaluated comparatively with non-targeted FITC-PAMAM NPs.
FITC-APP NPs exhibited an average hydrodynamic diameter of 32.23 ± 0.62 nm and a zeta potential of -4.36 ± 0.10 mV. Compared with non-targeted FITC-PAMAM NPs, FITC-APP NPs demonstrated significantly higher adhesion, uptake, and transport rates in BMEC and C6 cells, whereas no significant differences were observed in HEK-293 cells. Furthermore, FITC-APP NPs exerted stronger inhibitory effects on C6 cells and displayed enhanced antitumor activity in animal models relative to FITC-PAMAM NPs.
These results not only provided data support for the targeting characteristics of FITC-APP NPs, but also provided a method reference for the targeting performance assessment of brain-targeted nano-DDS.
PMID:
42683824
Bibliographic data and abstract were imported from PubMed on 02 Sep 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 5
- Comments 0